Serotonin Receptors in Myocardial Infarction: Friend or Foe?

被引:3
|
作者
Bahr, F. S. [1 ]
Ricke-Hoch, M. [2 ]
Ponimaskin, E. [1 ]
Mueller, F. E. [1 ]
机构
[1] Hannover Med Sch, Cellular Neurophysiol, D-30625 Hannover, Germany
[2] Hannover Med Sch, Cardiol & Angiol, D-30625 Hannover, Germany
来源
ACS CHEMICAL NEUROSCIENCE | 2024年 / 15卷 / 08期
关键词
Myocardial infarction; Serotonin receptors; 5-HT system; Cardiovascular system; Serotonin reuptakeinhibitors; Cardioprotection; CORONARY-HEART-DISEASE; 5-HT4; RECEPTOR; MESSENGER-RNA; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; SPLICE VARIANTS; 5-HYDROXYTRYPTAMINE(2B) RECEPTOR; CARDIOVASCULAR-DISEASE; REUPTAKE INHIBITORS; CARDIAC-HYPERTROPHY;
D O I
10.1021/acschemneuro.4c00031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acute myocardial infarction (AMI) is one of the leading causes of death worldwide and treatment costs pose a major burden on the global health care system. Despite the variety of treatment options, individual recovery can be still poor and the mortality rate, especially in the first few years after the event, remains high. Therefore, intense research is currently focused on identifying novel target molecules to improve the outcome following AMI. One of the potentially interesting targets is the serotonergic system (5-HT system), not at least because of its connection to mental disorders. It is known that patients suffering from AMI have an increased risk of developing depression and vice versa. This implicates that the 5-HT system can be affected in response to AMI and might thus represent a target structure for patients' treatment. This review aims to highlight the importance of the 5-HT system after AMI by describing the role of individual serotonin receptors (5-HTR) in the regulation of physiological and pathophysiological responses. It particularly focuses on the signaling pathways of the serotonin receptors 1, 2, 4, and 7, which are expressed in the cardiovascular system, during disease onset, and the following remodeling process. This overview also emphasizes the importance of the 5-HT system in AMI etiology and highlights 5-HTRs as potential treatment targets.
引用
收藏
页码:1619 / 1634
页数:16
相关论文
共 50 条
  • [31] Osteopontin in Vascular Disease Friend or Foe?
    Lok, Zoe Shin Yee
    Lyle, Alicia N.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 613 - 622
  • [32] Sulfur dioxide: foe or friend for life?
    Wang, Xin-Bao
    Cui, Hong
    Liu, Xiao-Hong
    Du, Jun-Bao
    HISTOLOGY AND HISTOPATHOLOGY, 2017, 32 (12) : 1231 - 1238
  • [33] Estrogen: Friend or Foe in Pulmonary Hypertension?
    White, R. James
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193 (10) : 1084 - 1086
  • [34] Dairy and cardiovascular health: Friend or foe?
    Markey, O.
    Vasilopoulou, D.
    Givens, D. I.
    Lovegrove, J. A.
    NUTRITION BULLETIN, 2014, 39 (02) : 161 - 171
  • [35] Opioids and the immune system - friend or foe
    Plein, Lisanne Mirja
    Rittner, Heike L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (14) : 2717 - 2725
  • [36] Amiodarone for atrial fibrillation: Friend or foe?
    Glover, Benedict M.
    Baranchuk, Adrian
    CARDIOLOGY JOURNAL, 2015, 22 (06) : 603 - 604
  • [37] TLR9: A friend or a foe
    Saber, Mona M.
    Monir, Nada
    Awad, Azza S.
    Elsherbiny, Marwa E.
    Zaki, Hala F.
    LIFE SCIENCES, 2022, 307
  • [38] Substance P-Friend or Foe
    Robinson, Prema
    Rodriguez, Emma
    Munoz, Miguel
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [39] Metabolically healthy obesity: a friend or foe?
    Jung, Chang Hee
    Lee, Woo Je
    Song, Kee-Ho
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (04) : 611 - 621
  • [40] Statins and Renal Disease: Friend or Foe?
    Abhishek Deshmukh
    Jawahar L. Mehta
    Current Atherosclerosis Reports, 2011, 13 : 57 - 63